BLRX revenueFY2025$1.18M
- FY YoY
- -95.9%
- 5Y CAGR
- +38.0%
BLRX revenue was $1.18M for fiscal 2025 (ended Dec 31, 2025), down 95.9% from fiscal 2024. Compound annual growth was +38.0% over 5 years.
BioLineRx Ltd. (BLRX) financials
For fiscal 2025 (ended Dec 31, 2025), BioLineRx Ltd. reported $1.18M of revenue and -$2.03M of net income.
- Revenue, FY2025
- $1.18M
- Revenue growth, YoY
- -95.9%
- Net income, FY2025
- -$2.03M
- Net margin
- -171.7%
- Free cash flow, FY2025
- -$8.10M
- EPS, diluted, FY2025
- $0.00
- Cash
- $3.25M
- P/S
- 6.67
- Market cap
- $7.9M
FY2020FY2025
FY2016FY2025
FY2016FY2025
BLRX revenue and earnings growth
BLRX net incomeFY2025-$2.03M
BLRX net income was -$2.03M for fiscal 2025 (ended Dec 31, 2025), compared with -$9.22M in fiscal 2024.
BLRX EPSFY2025$0.00
BLRX diluted EPS was $0.00 for fiscal 2025 (ended Dec 31, 2025).
BLRX free cash flowFY2025-$8.10M
BLRX free cash flow was -$8.10M for fiscal 2025 (ended Dec 31, 2025), compared with -$43.93M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.18M | $28.94M | $4.80M | $0 | $0 | $236.0K | - | - | - | - |
| Cost of revenue | $230.0K | $9.26M | $3.69M | $0 | $0 | - | - | - | - | - |
| Gross profit | $950.0K | $19.68M | $1.11M | $0 | $0 | - | - | - | - | - |
| Research and development | $8.09M | $9.15M | $12.52M | $17.63M | $19.47M | $18.17M | $23.44M | $19.81M | $19.51M | $11.18M |
| Selling, general and admin | $3.14M | $6.32M | $6.31M | $5.07M | $4.31M | $3.91M | $3.82M | $4.43M | $4.04M | $3.98M |
| Operating income | -$10.29M | -$20.41M | -$49.69M | -$29.16M | -$24.78M | -$22.93M | -$28.11M | -$25.61M | -$25.24M | -$16.51M |
| Interest expense | $1.25M | $9.07M | $2.14M | $1.79M | $984.0K | $1.47M | $2.28M | $473.0K | $21.0K | $22.0K |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | - | - | - |
| Net income | -$2.03M | -$9.22M | -$60.61M | -$24.95M | -$27.05M | -$30.02M | -$25.45M | -$22.96M | -$24.35M | -$15.84M |
| EPS, basic | $0.00 | -$0.01 | -$0.06 | -$0.03 | -$0.04 | -$0.12 | - | - | - | - |
| EPS, diluted | $0.00 | -$0.01 | -$0.06 | -$0.03 | -$0.04 | -$0.12 | - | - | - | - |
| Diluted shares | 2.47B | 1.20B | 963.4M | 774.0M | 662.9M | 252.8M | 146.4M | 108.6M | 90.0M | 56.1M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.25M | $10.44M | $4.25M | $10.59M | $12.99M | $16.83M | $5.30M | $3.40M | $5.11M | $2.47M |
| Inventory | $2.15M | $3.15M | $1.95M | $0 | - | - | - | - | - | - |
| Current assets | $23.68M | $27.10M | $47.18M | $52.00M | $57.40M | $22.88M | $28.21M | $31.98M | $50.38M | $36.10M |
| Total assets | $40.91M | $38.91M | $63.92M | $76.38M | $81.39M | $47.29M | $53.57M | $56.23M | $60.97M | $38.94M |
| Current liabilities | $12.12M | $15.41M | $42.78M | $10.68M | $9.72M | $10.64M | $11.97M | $6.75M | $6.72M | $3.66M |
| Short-term debt | $4.48M | $4.48M | $3.15M | $1.54M | $2.76M | $3.09M | $2.69M | $895.0K | $93.0K | $93.0K |
| Total debt | - | - | - | - | - | $5.83M | $8.49M | $8.73M | $250.0K | $343.0K |
| Total liabilities | $17.56M | $25.45M | $50.70M | $25.54M | $13.30M | $25.26M | $20.19M | $14.91M | $8.08M | $3.91M |
| Shareholders' equity | $18.20M | $13.46M | $13.22M | $50.84M | $68.09M | $22.03M | $33.38M | $41.32M | $52.88M | $35.03M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.07M | -$43.87M | -$22.61M | -$26.24M | -$23.57M | -$23.21M | -$22.67M | -$24.19M | -$20.55M | -$14.51M |
| Capital expenditures | $25.0K | $53.0K | $116.0K | $131.0K | $97.0K | $0 | $67.0K | $173.0K | $338.0K | $52.0K |
| Free cash flow | -$8.10M | -$43.93M | -$22.72M | -$26.37M | -$23.67M | -$23.21M | -$22.73M | -$24.36M | -$20.89M | -$14.56M |
| Investing cash flow | -$8.54M | $29.37M | $1.44M | $4.01M | -$38.22M | $16.67M | $5.26M | $9.55M | -$15.93M | $9.30M |
| Financing cash flow | $8.88M | $20.66M | $15.06M | $20.44M | $57.75M | $17.87M | $19.19M | $13.10M | $38.68M | $2.09M |
| Stock-based compensation | $396.0K | $1.14M | $2.32M | $2.25M | $1.50M | $1.27M | $1.76M | $2.53M | $1.51M | $1.07M |
| Depreciation and amortization | $523.0K | $4.07M | $1.38M | $654.0K | $703.0K | $934.0K | $940.0K | $545.0K | $481.0K | $482.0K |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -95.9% | 502.9% | - | - | -100.0% | - | - | - | - | - |
| Gross margin | 80.5% | 68.0% | 23.1% | - | - | - | - | - | - | - |
| Operating margin | -871.8% | -70.5% | -1035.3% | - | - | -9714.8% | - | - | - | - |
| Net margin | -171.7% | -31.9% | -1262.8% | - | - | -12720.8% | - | - | - | - |
| Free cash flow margin | -686.4% | -151.8% | -473.4% | - | - | -9833.1% | - | - | - | - |
| Return on equity | -11.1% | -68.5% | -458.4% | -49.1% | -39.7% | -136.3% | -76.2% | -55.6% | -46.1% | -45.2% |
| Return on assets | -5.0% | -23.7% | -94.8% | -32.7% | -33.2% | -63.5% | -47.5% | -40.8% | -39.9% | -40.7% |
| Current ratio | 1.95 | 1.76 | 1.10 | 4.87 | 5.91 | 2.15 | 2.36 | 4.74 | 7.49 | 9.86 |
| Debt to equity | - | - | - | - | - | 0.26 | 0.25 | 0.21 | 0.00 | 0.01 |
Source: XBRL data BioLineRx Ltd. files with the SEC, latest filing dated Mar 23, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
Foreign private issuers file annual reports with the SEC, so there are no quarterly statements here.
BLRX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| BLRX | $1.18M | -95.9% | -$2.03M | -171.7% | $7.9M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
BLRX FAQ
9 questionsWhat is BLRX revenue?
BioLineRx Ltd. (BLRX) reported $1.18M of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 95.9% from the year before.Is BLRX profitable?
No. BioLineRx Ltd. reported a net loss of $2.03M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does BLRX have?
BioLineRx Ltd. reported $3.25M in cash and cash equivalents on its most recent balance sheet in SEC filings.How fast is BLRX revenue growing?
BioLineRx Ltd.'s revenue changed -95.9% in fiscal 2025, to $1.18M. Its compound annual growth rate was +38.0% over 5 years.What is BLRX gross margin?
BioLineRx Ltd.'s gross profit was $950.0K on $1.18M of revenue for fiscal 2025 (ended Dec 31, 2025), a gross margin of 80.5%.What is BLRX free cash flow?
BioLineRx Ltd. generated -$8.10M of free cash flow for fiscal 2025 (ended Dec 31, 2025), which is operating cash flow of -$8.07M less capital expenditures.What is BLRX earnings per share?
Diluted earnings per share were $0.00 for fiscal 2025 (ended Dec 31, 2025), from SEC filings, restated for any stock split those filings show.When did BLRX last report financial results?
The latest statements here come from BioLineRx Ltd.'s 20-F filed on Mar 23, 2026, covering the period ended Dec 31, 2025.Where does this BLRX financial data come from?
Quantisnow builds these statements from the structured XBRL data BioLineRx Ltd. files with the SEC. It is provided for information only and is not investment advice.